Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flurpiridaz F18 PET vs SPECT in CAD
NCT01681524Phase 3Withdrawn
- Sponsor
- Lantheus Holdings, Inc.
- Start
- Nov 2012
- Primary completion
- Feb 2014
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of Flurpiridaz F 18 in coronary artery disease (CAD), sponsored by Lantheus Holdings, Inc. Primary endpoint: Blinded Image assessment for PET & SPECT perfusion and for interventional coronary angiography at 12 months. Planned start Nov 2012; status: withdrawn.
02
Drugs
Flurpiridaz F 18
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01681524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01681524.